A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase III
Latest Information Update: 26 Apr 2017
At a glance
- Drugs Nilvadipine (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms NILVAD
- 11 Jan 2017 Status changed to completed.
- 26 May 2015 Planned primary completion date changed from 1 May 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
- 26 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.